Metoclopramide as a modulator of cisplatin: Effects an pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 483-488

  Johnsson, Anders ^a   Kjellén, Elisabeth ^a   Wennerberg, Johan ^a   Pero, Ron ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adduct; Cisplatin; DNA; Metoclopramide

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; METOCLOPRAMIDE; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER SIZE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA REPAIR; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CISPLATIN; DNA ADDUCTS; DRUG SYNERGISM; FEMALE; KIDNEY; MALE; METOCLOPRAMIDE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASAL CAVITY; NEOPLASM TRANSPLANTATION; NOSE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029888398     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00014     Document Type: Article

References (20)

1. Timmer-Bosscha H, Mulder NH, de Vries EGE. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992; 66: 227-38.
2. Lyhak S, Kjellén E, Wennerberg J, Pero R. Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck Int J Radiat Oncol Biol Phys 1990; 19: 1419-24.
3. Kjellén E, Wennerberg J, Pero R. Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Br J Cancer 1989; 59: 247-50.
4. Lybak S, Wennerberg J, Kjellén E, Pero RW. Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anti-Cancer Drugs 1991; 2: 375-82.
5. Lybak S, Pero RW. The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human peripheral mononuclear leukocytes at clinically relevant doses. Carcinogenesis 1991; 12: 1613-7.
6. Olsson A, Sheng Y, Kjellén E, Pero RW. In vivo tumor measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 1995; 16: 1029-35.
7. Johnsson A, Olsson C, Nygren O, et al. Pharmacokinetics and tissue distribution in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 1995; 37: 23-31.
8. Osieka R, Houchens DP, Goldin A, Johnson RK. Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 1977; 40: 2640-50.
9. Lesser ML, Braun HI, Helson L. Statistical methods for measuring and comparing treatment efficacies: application to nude mice experimentation. Exp Cell Biol 1980; 48: 126-37.
10. Herman R, Steel GG. Induced and inherent resistance to alkylating agents in human small cell brochial carcinoma xenografts. Br J Cancer 1984; 49: 431-6.
11. Begg AC. Analysis of growth delay data: potential pitfalls. Br J Cancer 1980; 41 (suppl): 93.
12. Johnsson A, Olsson C, Andersson H, Cavallin-Ståhl E. Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 1994; 17: 142-50.
13. Terheggen PMAB, Floot BGJ, Scherer E, et al. Immunocytochemical detection of interaction products of cis-diammindichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissues. Cancer Res 1987; 47: 6719-25.
14. Reed E, Sauerhoff S, Poirier MC. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure - a novel use of graphite furnace spectrometry. Atom Spectrosc 1988; 9: 93-5.
15. Ma J, Verweij J, Kolker HJ, et al. Pharmacokinetic-dynamic relationship in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 1994; 69: 858-62.
16. Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC. Cis-diamminedichloroplatinum(II)-DNA adduct formation in renal, gonadal and tumor tissues of male and female rats. Cancer Res 1987; 47: 718-22.
17. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 1987; 47: 3000-4.
18. Terheggen PMAB, Dijkman R, Begg AC, et al. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)-platinum(II) with DNA in cells from platinum-treated patients. Cancer Res 1988; 48: 5597-603.
19. Stewart DJ, Dulberg C, Molepo JM, et al. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Cancer Chemother Pharmacol 1994; 34: 14-22.
20. Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin-induced emisis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 1985; 55: 527-34.